CUSIP: 30233M107
Q2 2019 13F Holders as of 30 Jun 2019
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
18,560,037
-
Share change
-
+288,686
-
Total reported value
-
$4,452,000
-
Price per share
-
$0.24
-
Number of holders
-
16
-
Value change
-
+$70,442
-
Number of buys
-
5
-
Number of sells
-
3
Quarterly Holders Quick Answers
What is CUSIP 30233M107?
CUSIP 30233M107 identifies EYEG - EYEGATE PHARMACEUTICALS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q3 2019
-
Previous quarter:
Q1 2019
Recent filing periods for CUSIP 30233M107:
Institutional Holders of EYEGATE PHARMACEUTICALS INC - COM (EYEG) as of Q2 2019
As of 30 Jun 2019,
EYEGATE PHARMACEUTICALS INC - COM (EYEG) was held by
16 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
18,560,037 shares.
The largest 10 holders included
ARMISTICE CAPITAL, LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, VANGUARD GROUP INC, PANAGORA ASSET MANAGEMENT INC, UBS Group AG, TWO SIGMA SECURITIES, LLC, US BANCORP \DE\, Golden State Wealth Management, LLC, ACADIAN ASSET MANAGEMENT LLC, and WEDBUSH SECURITIES INC.
This page lists
16
institutional shareholders reporting positions in this security
for the Q2 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.